- Home
- BRTX vs NEUP Comparison
BRTX vs NEUP Comparison
Compare BRTX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- NEUP
- Stock Information
- Founded
- BRTX 1997
- NEUP 1996
- Country
- BRTX United States
- NEUP United States
- Employees
- BRTX N/A
- NEUP N/A
- Industry
- BRTX Managed Health Care
- NEUP
- Sector
- BRTX Health Care
- NEUP
- Exchange
- BRTX Nasdaq
- NEUP Nasdaq
- Market Cap
- BRTX 12.5M
- NEUP 12.7M
- IPO Year
- BRTX N/A
- NEUP N/A
- Fundamental
- Price
- BRTX $1.84
- NEUP $11.33
- Analyst Decision
- BRTX
- NEUP Strong Buy
- Analyst Count
- BRTX 0
- NEUP 1
- Target Price
- BRTX N/A
- NEUP $21.00
- AVG Volume (30 Days)
- BRTX 88.0K
- NEUP 58.6K
- Earning Date
- BRTX 08-12-2025
- NEUP 08-28-2025
- Dividend Yield
- BRTX N/A
- NEUP N/A
- EPS Growth
- BRTX N/A
- NEUP N/A
- EPS
- BRTX N/A
- NEUP 0.00
- Revenue
- BRTX $605,200.00
- NEUP $15,662,715.00
- Revenue This Year
- BRTX $232.67
- NEUP N/A
- Revenue Next Year
- BRTX $52.92
- NEUP N/A
- P/E Ratio
- BRTX N/A
- NEUP $3.66
- Revenue Growth
- BRTX 247.62
- NEUP N/A
- 52 Week Low
- BRTX $1.21
- NEUP $2.90
- 52 Week High
- BRTX $2.55
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- BRTX 72.78
- NEUP 71.74
- Support Level
- BRTX $1.51
- NEUP $6.82
- Resistance Level
- BRTX $1.56
- NEUP $8.81
- Average True Range (ATR)
- BRTX 0.08
- NEUP 1.07
- MACD
- BRTX 0.04
- NEUP 0.44
- Stochastic Oscillator
- BRTX 89.91
- NEUP 69.20
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.